JPRN-jRCTs021210039
Recruiting
Phase 2
Phase II study to efficacy of budesonide for the treatment of intestinal acute graft-versus-host disease in allogeneic hematopoietic stem cell transplant recipients.
Yamashita Takaya0 sites20 target enrollmentSeptember 29, 2021
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Yamashita Takaya
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •(1\) Intestinal acute GVHD
- •(2\) Untreated
- •(3\) Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0 to 2
- •(4\) Written informed consent
Exclusion Criteria
- •(1\) Post\-treatment for GVHD
- •(2\) Skin GVHD stage 3 or higher, liver GVHD stage 1 or higher.
- •(3\) Active infection
- •(4\) Intestinal disease due to other causes (e.g. CMV enteritis, thrombotic microangiopathy)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Budesonide for Induction of Remission in Incomplete Microscopic ColitisIncomplete Microscopic ColitisNCT02142634Dr. Falk Pharma GmbH44
Recruiting
Phase 3
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoEEosinophilic EsophagitisNCT06596252Dr. Falk Pharma GmbH308
Active, not recruiting
Phase 1
Evaluation of the efficacy of topical budesonide in the treatment of esophagogastroduodenal Crohn's disease in childreCrohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2020-004168-24-PLMedical University of Warsaw138
Recruiting
Phase 3
Effectiveness of the Treatment With Budesonide Nebuliser among Patients with Acute AsthmaIRCT20170531034256N2Shahid Beheshti University of Medical Sciences70
Unknown
Phase 3
Investigation of Safety and Efficacy of Budesonide Inhalation Suspension in the Long-Term Use in Japanese Children With Bronchial Asthma (Open Long-Term Extension Study Following Study SD-004-0765AsthmaJPRN-jRCT2080220398AstraZeneca